Russia Offered Pfizer to Start COVID-19 Vaccine Combination Studies

Russia Offered Pfizer to Start COVID-19 Vaccine Combination Studies

Russia asked Pfizer to start studies in order to check the possibility of a combination between their vaccine and Pfizer's. Keep reading to find out all the details. Read on. 

Russia asked Pfizer to start studies in order to check the possibility of a combination between their vaccine and Pfizer's. Keep reading to find out all the details. Read on. 

The Russian Direct Investment Fund (RDIF) made the Sputnik V vaccine available again to Pfizer to carry out combination studies between the two inoculants.

They did so through the Sputnik V social networks, sharing a Bloomberg article entitled "The increase in COVID in Israel shows the world what will come next" in which it is explained how the Asian country, despite having had a of the fastest vaccination campaigns, "it is now one of the largest pandemic hot spots in the world."

The Russian Direct Investment Fund (RDIF) made the Sputnik V vaccine available again to Pfizer to carry out combination studies between the two inoculants.

After tweeting the article, from @sputnikvaccine they shared a thread that they had published on August 11 in which it was explained about the increase in cases in the United States and Israel as a result of the irruption of the Delta variant.

After tweeting the article, from @sputnikvaccine they shared a thread that they had published on August 11 in which it was explained about the increase in cases in the United States

"The increase in Delta variant cases in the US and Israel shows that mRNA vaccines need a heterogeneous boost to strengthen and prolong the immune response. Sputnik V pioneered the combination approach and pooled assays and showed a 83.1% efficiency compared to the Delta variant. Today RDIF offers Pfizer to start the test with Sputnik Light as a reinforcement ", they offered from Russia.

Subsequently, they indicated that the Russian vaccine was the first to be offered, in November last year, to undergo combination studies together with the inoculants developed by Oxford-AstraZeneca, Moderna and Sinopharm.

Related Articles

More News

More News